Home Antibody All anti-CBL antibodies
Anti-CBL PHOSPHO Antibody EPR2227
|A phospho specific peptide corresponding to residues surrounding tyrosine 674 of human Cbl were used as an immunogen. This antibody detects Cbl phosphorylated on tyrosine 674.|
|Human (Does not react with: Mouse, Rat)
||Lot dependent; please refer to CoA along with shipment
||WB: 1:1000 - 2000;
|Store at -20 °C. Buffer: Antibody buffer, sodium azide, glycerol, and BSA. Stable for 12 months from date of receipt.|
|Homo sapiens Cbl proto-oncogene, E3 ubiquitin protein ligase (CBL)|
|C-CBL; CBL2; FRA11B; NSLL; RNF55|
Entrez Gene 867 Human
|c-Cbl, product of c-cbl proto-oncogene, is a 120 kDa cytoplasmic protein involved in tyrosine kinase-dependent signaling pathways (1-3). c-Cbl is one of the earliest targets of tyrosine phosphorylation in response to a number of cellular stimuli. For instance, stimulation of growth factor receptors by EGF, PDGF, NGF and FGF, results in c-Cbl tyrosine phosphorylation, in lymphoid and other cell lines (4). It has been demonstrated that certain tyrosines are the major phosphorylation sites of c-Cbl in T cells in response to pervanadate treatment, as well as in response to TcR/CD3 ligation. Cbl also enhances migration of v-Abl-transformed NIH 3T3 fibroblasts. This effect of Cbl depends on its tyrosine phosphorylation, which is required for binding of PI-3' kinase to c-Cbl (5)|
|Transcription FactorsDruggable Genome ErbB signaling pathwayUbiquitin mediated proteolysisEndocytosisJak-STAT signaling pathwayT cell receptor signaling pathwayInsulin signaling pathwayMore Pathways >> |
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Flow cytometric analysis of permeabilized Jurkat cells, un-treated (green) or pervanadate treated (red) using TA310245 at a 1/20 dilution, and pervanadate-treated Jurkat cells using the same antibody pre-incubated with phospho-CBL peptide (blue) or non-phospho-CBL peptide (orange).